Covid-19 vaccine researchers hope to be able to restart trials soon.

AstraZeneca halted its trials last week after a severe reaction that may not have been induced by the vaccine.

CEO Pascal Soriot said in a private call with investors that a woman in the UK developed neurological issues.

Her condition is improving and she was expected to return home this week.

Reports earlier said she may have developed a condition called transverse myelitis.

Researchers are looking at whether it could have been caused by the experimental vaccine.

The AstraZeneca/Oxford University vaccine partnership is one of the frontrunners in the vaccine race.

Oxford was among the 1st few companies to publish promising results for immunity/

The vaccine is one of 3 advanced experimental drugs that have reached Phase 3 trials in America and Europe.

AstraZeneca has deals with the US and other countries for hundreds of millions of doses if the vaccine is safe and effective.